Efficiency of iloprost treatment for osseous malperfusion.

Abstract

Insufficient osseous blood supply results in bone marrow oedema (BMO) and/or avascular necrosis (AVN). One treatment option to support osseous perfusion is the application of stable prostacycline analog iloprost. In this clinical study, 95 patients were treated with iloprost for BMO/AVN. One hundred eighty-six bones were affected by BMO/AVN before treatment. Average follow-up was 33.0 ± 17.6 months. Pain levels could be reduced (e.g. visual analogue scale, 5.0 ± 2.2 points reduced to 1.7 ± 2.2 points) and functional scores improved (Harris hip score, 52 ± 21 points to 79 ± 17 points) in the course of treatment. According to current data, healing of advanced stages of osteonecrosis is not possible. However, the results of this case series confirm previous findings that in early stages of insufficient osseous blood flow iloprost can contribute to the relief of pain and improve joint function.

• Authors: Marcus Jäger, Christoph Zilkens, Bernd Bittersohl, Travis Matheney, Gordana Kozina, Dirk Blondin, Rüdiger Krauspe
• Journal: International orthopaedics (Int Orthop) Vol. 35 Issue 5 Pg. 761-5 (May 2011) ISSN: 1432-5195 [Electronic] Germany
• PMID: 20306261 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Platelet Aggregation Inhibitors
• Iloprost

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Bone Marrow Diseases (diagnostic imaging, drug therapy, pathology)
• Edema (drug therapy)
• Female
• Humans
• Iloprost (therapeutic use)
• Joints (drug effects, physiopathology)
• Male
• Middle Aged
• Osteonecrosis (diagnostic imaging, drug therapy, pathology)
• Platelet Aggregation Inhibitors (therapeutic use)
• Prospective Studies
• Radiography
• Range of Motion, Articular
• Treatment Outcome
• Young Adult